Nebu-Flow develops nebulisers for respiratory drug delivery, utilizing a patented aerosol formation technology for efficient delivery of hard-to-nebulise drugs.

Nebu-Flow

Nebu~Flow is developing next generation of nebulisers to unlock delivery of next generation of inhaled drugs

Ascension Life Fund

SCVC

SIS Ventures

Foresight Williams

Nebu~Flow 

📦It's packing time! 📦 
We are getting ready for our move to a fantastic new location. Stay tuned for more updates... 🏢✨

Glasgow-based medical device firm Nebu~Flow has secured an additional £4.7 million of investment to help accelerate the next generation of inhaled drugs for patients with respiratory conditions. 

#Tech | #News | #Glasgow

Today's The Herald Scotland reports on Nebu~Flow  securing an additional £4.7 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide.  The company’s nebuliser platform has been developed to provide a number of advantages over existing technologies. Overall, the worldwide inhalable drug market was valued at approximately $33 billion in 2023, with the nebuliser market valued at over $1 billion.  

The funding round was led by SCVC, a leading UK-based venture capital firm that invests in early-stage deep tech spinouts, and was supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.

I am pleased to announce that Foresight Group has provided follow on investment to Nebu~Flow .

Congratulations to Elijah Nazarzadeh and the rest of the team. I look forward to continue working with you on the next stage of the journey.

I am delighted to announce Nebu~Flow ’s latest investment from a group of brilliant investors, bringing the total investment in our new category of nebulisers, transforming inhalation drug delivery, to above £8.5m. 

Thanks to all our investors with their continued support SCVC, Scottish Enterprise, Foresight Group, WAE, SIS Ventures ,Ascension Life Fund, Conduit Connect

#startup #medicaldevices #nebuliser #RNA #respiratory #inhalation

Huge congratulations to Elijah Nazarzadeh and the entire Nebu~Flow team for raising £4.7m in seed funding to optimize the next generation of inhaled drugs for patients with respiratory disorders.

The Conduit EIS Impact Fund are delighted to have backed this round alongside SCVC, Scottish Enterprise, Foresight Group, WAE, SIS Ventures , Ascension Life Fund.

We can't wait to see what's next! ✨🚀 

Read more: https://lnkd.in/eKjejhBC

#RNA #Nebluiser #inhalation

Metric
Company Name	Nebu-Flow
Symbol
MSH ID	COM:NEBUFLOW
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	GB
Stage
Employee Count	16
Website	nebuflow.com
LinkedIn	nebuflow
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEBUFLOW

Nebu-Flow

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue